Results 291 to 300 of about 862,879 (325)

An Integrated Business Strategy for the Twin Transition: Leveraging Digital Product Passports and Circular Economy Models

Business Strategy and the Environment, EarlyView.
ABSTRACT Companies face significant challenges in implementing digital transformation, often because of the use of fragmented strategies and limited cross‐functional coordination. Furthermore, not all digital innovations align with sustainability objectives.
Idiano D'Adamo, Luciano Fratocchi, Chiara Grosso, Madjid Tavana   +3 more
wiley   +1 more source

Voclosporin‐induced gingival enlargement: A case report

Clinical Advances in Periodontics, EarlyView.
Abstract Background Drug‐influenced gingival enlargement (DIGE) is a recognized adverse effect of certain medications, particularly immunosuppressants like cyclosporin and tacrolimus. However, there have been no documented cases of DIGE associated with voclosporin, a newer calcineurin inhibitor used primarily to treat lupus nephritis.
Francesca Racca, Jessica M. Greco, Dimitris N. Tatakis   +2 more
wiley   +1 more source

A novel complement C3 inhibitor CP40-KK protects against experimental pulmonary arterial hypertension via an inflammasome NLRP3 associated pathway. [PDF]

J Transl Med
Dai L, Chen Y, Wu J, He Z, Zhang Y, Zhang W, Xie Y, Zeng H, Zhong X.   +8 more
europepmc   +1 more source

Complement C3 From Astrocytes Plays Significant Roles in Sustained Activation of Microglia and Cognitive Dysfunctions Triggered by Systemic Inflammation After Laparotomy in Adult Male Mice. [PDF]

J Neuroimmune Pharmacol
Chen Y, Chu JM, Wong GT, Chang RC.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Complement C3 Deficiency

Encyclopedia of Medical Immunology, 2020
A. Ghannam, C. Drouet
semanticscholar   +3 more sources

Complement C3-targeted therapy in C3 glomerulopathy, a prototype of complement-mediated kidney diseases

Seminars in Immunology, 2022
C3 glomerulopathy (C3G) is a rare and complex kidney disease that primarily affects young adults. Renal outcomes remain poor in the absence of specific treatment. C3G is driven by uncontrolled overactivation of the alternative complement pathway, which is mainly of acquired origin.
Marie-Sophie, Meuleman, Anne, Grunenwald, Sophie, Chauvet   +2 more
openaire   +2 more sources

The role of complement in C3 glomerulopathy

Molecular Immunology, 2015
C3 glomerulopathy describes a spectrum of disorders with glomerular pathology associated with C3 cleavage product deposition and with defective complement action and regulation (Fakhouri et al., 2010; Sethi et al., 2012b). Kidney biopsies from these patients show glomerular accumulation or deposition of C3 cleavage fragments, but no or minor deposition
Marina Noris, Sally Johnson, Richard J.H. Smith, Véronique Frémeaux-Bacchi, Peter F. Zipfel, Peter F. Zipfel, Qian Chen, Christine Skerka, Santiago Rodríguez de Córdoba, Matthew C. Pickering, Timothy H.J. Goodship, Clara Nester, Thorsten Wiech   +12 more
openaire   +3 more sources

Complement inhibition in C3 glomerulopathy

Seminars in Immunology, 2016
C3 glomerulopathy (C3G) describes a spectrum of glomerular diseases defined by shared renal biopsy pathology: a predominance of C3 deposition on immunofluorescence with electron microscopy permitting disease sub-classification. Complement dysregulation underlies the observed pathology, a causal relationship that is supported by well described studies ...
Carla M. Nester, Richard J.H. Smith
openaire   +3 more sources